LIMD2 Regulates Key Steps of Metastasis Cascade in Papillary Thyroid Cancer Cells via MAPK Crosstalk

LIMD2 Regulates Key Steps of Metastasis Cascade in Papillary Thyroid Cancer Cells via MAPK Crosstalk

Although papillary thyroid carcinoma (PTC) has a good prognosis, 20–90% of patients show metastasis to regional lymph nodes and 10–15% of patients show metastasis to distant sites. Metastatic disease represents the main clinical challenge that impacts survival rate. We previously showed that LIMD2 w...

Full description

Bibliographic Details
Main Authors:	Rodrigo Pinheiro Araldi, Thatiana Correa de Melo, Débora Levy, Dener Madeiro de Souza, Beatriz Maurício, Gabriel Avelar Colozza-Gama, Sergio Paulo Bydlowski, Hongzhuang Peng, Frank J. Rauscher, Janete Maria Cerutti
Format:	Article
Language:	English
Published:	MDPI AG 2020-11-01
Series:	Cells
Subjects:	papillary thyroid carcinoma LIMD2 BRAF V600E CRISPR/Cas9 epithelial-to-mesenchymal transition
Online Access:	https://www.mdpi.com/2073-4409/9/11/2522

Similar Items

LIMD1‐AS1 suppressed non‐small cell lung cancer progression through stabilizing LIMD1 mRNA via hnRNP U
by: Jianyuan Pan, et al.
Published: (2020-06-01)

A HIF–LIMD1 negative feedback mechanism mitigates the pro‐tumorigenic effects of hypoxia
by: Daniel E Foxler, et al.
Published: (2018-06-01)

Rethinking the role of oncogenes in papillary thyroid cancer initiation
by: Mario eVitale
Published: (2012-06-01)

Papillary thyroid cancer and cutaneous melanoma: An often underrecognized pair
by: Michelle Chernyak, BS, et al.
Published: (2024-08-01)

Clinical response to dabrafenib plus trametinib in BRAF V600E mutated papillary craniopharyngiomas: a case report and literature review
by: Paul Hanona, et al.
Published: (2024-11-01)

Resolving the role of podoplanin in the motility of papillary thyroid carcinoma-derived cells using RNA sequencing
by: Damian Mielecki, et al.
Published: (2023-01-01)

LIMD1-AS1 promotes the progression of prostate cancer and affects the function of prostate cancer cells by down-regulating miR-29c-3p
by: Yongsheng Yu, et al.
Published: (2024-12-01)

Beneficial effects of vemurafenib on craniopharyngioma carrying BRAF-V600E mutation
by: WANG Xi, YE Ting, NIE Min, WU Xueyan, MAO Jiangfeng
Published: (2024-06-01)

Association of BRAF V600E immunoexpression with clinicopathological variant groups in papillary thyroid carcinoma
by: Hung Nguyen Van, et al.
Published: (2022-12-01)

BRAF V600E mutation is associated with aggressive features in papillary thyroid carcinomas ≤ 1.5 cm
by: Jennifer A. Silver, et al.
Published: (2021-11-01)

Prognostic Significance of BRAF V600E Mutation and CPSF2 Protein Expression in Papillary Thyroid Cancer
by: Irena Ivković, et al.
Published: (2022-12-01)

MRI-Based Texture Analysis for Preoperative Prediction of BRAF V600E Mutation in Papillary Thyroid Carcinoma
by: Zheng T, et al.
Published: (2023-01-01)

Treatment with BRAF/MEK: inhibitors in mutant BRAF V600E papillary craniopharyngioma
by: Eva Marie Erfurth, et al.
Published: (2024-12-01)

Risk factors for central lymph node metastasis in patients with papillary thyroid carcinoma: a retrospective study
by: Jiachen Du, et al.
Published: (2023-11-01)

Spontaneous rupture of malignant papillary craniopharyngioma with CSF seeding and metastatic deposits: A case report and literature review
by: Asfand Baig Mirza, et al.
Published: (2022-01-01)

Association of <i>BRAF</i> V600E Mutant Allele Proportion with the Dissemination Stage of Papillary Thyroid Cancer
by: Ivan Blazekovic, et al.
Published: (2024-02-01)

Relevance and clinicopathologic relationship of BRAF V600E, TERT and NRAS mutations for papillary thyroid carcinoma patients in Northwest China
by: Meiling Huang, et al.
Published: (2019-07-01)

Dramatic Therapeutic Response to Dabrafenib Plus Trametinib in BRAF V600E Mutated Papillary Craniopharyngiomas: A Case Report and Literature Review
by: Morena Fasano, et al.
Published: (2022-01-01)

Digital Papillary Adenocarcinoma: The Detection of Low-Risk Human Papillomaviruses and the <i>BRAF</i> p.V600E Mutation in a Subset of Cases
by: Feifan Chen, et al.
Published: (2024-06-01)

Immunohistochemistry Helps to Distinguish Noninvasive Follicular Thyroid Neoplasm with Papillary-like Nuclear Features/Noninvasive Encapsulated Follicular Variant of Papillary Thyroid Carcinoma with Other Follicular Thyroid Lesions
by: Hao-Wen Chuang, et al.
Published: (2021-11-01)

A Case of Concomitant Lung Adenocarcinoma and Pleural Metastasis of Papillary Thyroid Carcinoma With BRAF V600E Mutation
by: Akinari Atsumi, et al.
Published: (2025-02-01)

Developing Models to Predict <i>BRAF</i>V600E and <i>RAS</i> Mutational Status in Papillary Thyroid Carcinoma Using Clinicopathological Features and pERK1/2 Immunohistochemistry Expression
by: Agnes Stephanie Harahap, et al.
Published: (2023-10-01)

Expressions of miRNAs in Papillary Thyroid Carcinoma and Their Associations with the BRAF Mutation and Clinicopathological Features
by: Song I Yang, et al.
Published: (2020-06-01)

The molecular pathogenesis of craniopharyngiomas
by: Marina Lanciotti Campanini, et al.
Published: (2023-02-01)

Coexistence of BRAFV600E mutation and EGFR overexpression is highly associated with adverse clinicopathological features of papillary thyroid carcinoma
by: Paunović Ivan, et al.
Published: (2020-01-01)

Characteristics of central compartment lymph node metastasis in patients with unilateral cN0 papillary thyroid carcinoma and prophylactic dissection
by: LIU Wei, WANG Cong, XUE Anwei, ZHAO Junjie, WANG Zhenglin
Published: (2021-03-01)

Comparative study between Immunohistochemistry and Molecular method in detection of BRAF V600E mutation in papillary thyroid carcinoma
by: Sarah Ali Darweesh, et al.
Published: (2023-12-01)

Role of contrast-enhanced ultrasound with time-intensity curve analysis about thyroid nodule and parenchyma for differentiating BRAF V600E mutation status
by: Zhipeng Hu, et al.
Published: (2025-02-01)

Correlation analysis between BRAFV600E mutation and ultrasonic and clinical features of papillary thyroid cancer
by: Jiahao Wen, et al.
Published: (2024-05-01)

BRAFV600E/pTERT double mutated papillary thyroid cancers exhibit immune gene suppression
by: Ana-Maria Sigarteu Chindris, et al.
Published: (2024-12-01)

Iodine nutritional status is not a direct factor in the prevalence of the BRAFV600E mutation in papillary thyroid cancer
by: Yan-Yu Lin, et al.
Published: (2023-01-01)

Clinical implications of the BRAF mutation in papillary thyroid carcinoma and chronic lymphocytic thyroiditis
by: Woon Won Kim, et al.
Published: (2018-01-01)

Deep Small RNA Sequencing of BRAF V600E Mutated Papillary Thyroid Carcinoma With Lymph Node Metastasis
by: Azliana Mohamad Yusof, et al.
Published: (2019-10-01)

Deep learning-based multifeature integration robustly predicts central lymph node metastasis in papillary thyroid cancer
by: Zhongzhi Wang, et al.
Published: (2023-02-01)

Younger Than 55 Years Old and BRAF V600E Mutation are Risk Factors for Lymph Node Metastasis in Papillary Thyroid Carcinomas ≤1.0 cm but Not in >1.0 cm
by: Lai Y, et al.
Published: (2023-04-01)

Collision tumor of a papillary and follicular thyroid carcinoma: a case report
by: Kanako Kawasaki, et al.
Published: (2023-08-01)

Neoadjuvant BRAF and MEK inhibitor therapy elicits pathological complete response in stage IIIA non‐small cell lung cancer harboring BRAF V600E mutation: A case report
by: Zhicheng Huang, et al.
Published: (2024-08-01)

High BRAF V600 Mutation Level Associated with Worse Outcome in Metastatic Melanoma Patients Receiving BRAF and MEK Inhibitors
by: Ariane Fizazi, et al.
Published: (2024-11-01)

Anlotinib may have a therapeutic effect on papillary craniopharyngiomas without the BRAFv600e mutation
by: Yilamujiang Ainiwan, et al.
Published: (2025-03-01)

Long-term outcomes of follicular variant vs classic papillary thyroid carcinoma
by: Lauren E Henke, et al.
Published: (2018-11-01)